drugset
drugset / Trial / NCT05101486

A Study of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 Years

NCT05101486 ↗

Phase 3 Completed 755 enrolled Janssen Vaccines & Prevention B.V.
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study is to demonstrate non-inferiority in terms of humoral immune responses of Ad26.RSV.preF-based study vaccine lots representative of different aged vaccine in comparison to a non-aged Ad26.RSV.preF-based study vaccine lot.

Timeline

Start
2021-11-01
Primary completion
2022-03-28
Completion
2022-09-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Ad26.RSV.preF-based vaccine Vaccine — Intramuscular

Indications

respiratory syncytial virus infectious disease